{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,18]],"date-time":"2026-05-18T23:01:33Z","timestamp":1779145293554,"version":"3.51.4"},"reference-count":51,"publisher":"Wiley","issue":"3","license":[{"start":{"date-parts":[[2015,5,12]],"date-time":"2015-05-12T00:00:00Z","timestamp":1431388800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cardiovascular Therapeutics"],"published-print":{"date-parts":[[2015,6]]},"abstract":"<jats:title>Summary<\/jats:title><jats:sec><jats:title>Aims<\/jats:title><jats:p>Methadone has been associated with QTc prolongation and ventricular arrhythmias but the prevalence of QTc prolongation and association with ventricular arrhythmias remains unclear. We investigated this in our inner city urban community (Bronx, New York) that has a large number of patients on methadone.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>Telemetry records, nursing documentation and electronic charts of 291 patients spanning856 encounters were evaluated. QT was manually measured from ECG utilizing standardized QT measurement guidelines and was corrected for heart rate using Hodges formula. QTc &gt;470 ms in males and &gt;480 ms in females was considered to be prolonged.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Patients had prolonged QTc, QTc &gt;500 ms and ventricular arrhythmias during 25.6%, 14.1% and 3.4% of encounters, respectively. There was a very weak dose dependent relationship between methadone dose and QTc (Spearman's rho = 0.09).In addition to methadone, patients were on at least one QT prolonging drugs during 39% of the encounters. Patients who were receiving two interacting drugs in addition to methadone had the highest prevalence (29%) of QTc prolongation.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>Although the prevalence of QTc prolongation among patients on methadone therapy is high, the prevalence of ventricular arrhythmia is relatively low. Hospitalized patients on sustained methadone therapy are frequently on multiple additional QTc prolonging drugs. There is no significant dose dependent relationship between methadone dose and QTc. However, the concurrent use of methadone and interacting drugs lead to an increased prevalence of QTc prolongation.<\/jats:p><\/jats:sec>","DOI":"10.1111\/1755-5922.12120","type":"journal-article","created":{"date-parts":[[2015,4,1]],"date-time":"2015-04-01T14:19:37Z","timestamp":1427897977000},"page":"127-133","source":"Crossref","is-referenced-by-count":10,"title":["Methadone Therapy in Underserved Urban Community: <scp>QT<\/scp>c Prolongation and Life\u2010Threatening Ventricular Arrhythmias"],"prefix":"10.1111","volume":"33","author":[{"given":"Mohsin","family":"Chowdhury","sequence":"first","affiliation":[{"name":"Department of Internal Medicine Yale School of Medicine\/Yale\u2010New Haven Hospital New Haven CT USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jason","family":"Wong","sequence":"additional","affiliation":[{"name":"Department of Pharmacy Yale\u2010New Haven Hospital New Haven CT USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Angela","family":"Cheng","sequence":"additional","affiliation":[{"name":"Department of Pharmacy Montefiore Medical Center Bronx NY USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael","family":"Khilkin","sequence":"additional","affiliation":[{"name":"Department of Critical Care Medicine Montefiore Medical Center Bronx NY USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eugen","family":"Palma","sequence":"additional","affiliation":[{"name":"Department of Cardiovascular Medicine Montefiore Medical Center Bronx NY USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2015,5,12]]},"reference":[{"key":"e_1_2_7_2_1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.1965.03090080008002"},{"key":"e_1_2_7_3_1","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-150-6-200903170-00103"},{"key":"e_1_2_7_4_1","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-158-10-201305210-00008"},{"key":"e_1_2_7_5_1","doi-asserted-by":"publisher","DOI":"10.1007\/s10840-009-9465-9"},{"key":"e_1_2_7_6_1","doi-asserted-by":"publisher","DOI":"10.1001\/archinte.166.12.1280"},{"key":"e_1_2_7_7_1","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-137-6-200209170-00010"},{"key":"e_1_2_7_8_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.amjcard.2004.11.055"},{"key":"e_1_2_7_9_1","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-139-2-200307150-00021"},{"key":"e_1_2_7_10_1","doi-asserted-by":"publisher","DOI":"10.1001\/archinte.167.22.2469"},{"key":"e_1_2_7_11_1","doi-asserted-by":"publisher","DOI":"10.3109\/00952990.2013.804525"},{"key":"e_1_2_7_12_1","doi-asserted-by":"publisher","DOI":"10.1592\/phco.2005.25.11.1523"},{"key":"e_1_2_7_13_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0304-3959(03)00205-7"},{"key":"e_1_2_7_14_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jpainsymman.2004.06.012"},{"key":"e_1_2_7_15_1","doi-asserted-by":"publisher","DOI":"10.1592\/phco.23.6.802.32186"},{"key":"e_1_2_7_16_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1465-3362.2010.00237.x"},{"key":"e_1_2_7_17_1","doi-asserted-by":"publisher","DOI":"10.1007\/s12245-008-0052-0"},{"key":"e_1_2_7_18_1","doi-asserted-by":"publisher","DOI":"10.2146\/ajhp070392"},{"key":"e_1_2_7_19_1","unstructured":"Laboratories R: Dolophine hydrochloride [package insert]. In: Accessed atwww.accessdatafda.gov\/drugsatfda_docs\/label\/2006\/006134s028lbl.pdfon 15 April 2014. Edited by Roxane Laboratories Columbus OH;2006."},{"key":"e_1_2_7_20_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jpainsymman.2007.11.003"},{"key":"e_1_2_7_21_1","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-150-6-200903170-00111"},{"key":"e_1_2_7_22_1","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-151-3-200908040-00016"},{"key":"e_1_2_7_23_1","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-151-3-200908040-00013"},{"key":"e_1_2_7_24_1","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-151-3-200908040-00014"},{"key":"e_1_2_7_25_1","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-151-3-200908040-00015"},{"key":"e_1_2_7_26_1","doi-asserted-by":"publisher","DOI":"10.1002\/pds.1112"},{"key":"e_1_2_7_27_1","unstructured":"AZCERT.Drugs that prolong the QT interval and\/or induce Torsades de Pointes ventricular arrhythmia. Acccesed atwww.azcert.org\/medical-pros\/drug-lists\/drug-lists.cfmon 12 February 2014; Arizona CERT 2014."},{"key":"e_1_2_7_28_1","doi-asserted-by":"publisher","DOI":"10.1067\/mhj.2002.125804"},{"key":"e_1_2_7_29_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1056-8719(03)00008-X"},{"key":"e_1_2_7_30_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jelectrocard.2004.08.030"},{"key":"e_1_2_7_31_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.hrthm.2006.05.023"},{"key":"e_1_2_7_32_1","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.109.192704"},{"key":"e_1_2_7_33_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1360-0443.2009.02549.x"},{"key":"e_1_2_7_34_1","doi-asserted-by":"publisher","DOI":"10.1136\/hrt.2006.100180"},{"key":"e_1_2_7_35_1","doi-asserted-by":"publisher","DOI":"10.1038\/clpt.2011.273"},{"key":"e_1_2_7_36_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1360-0443.2006.01668.x"},{"key":"e_1_2_7_37_1","doi-asserted-by":"publisher","DOI":"10.1159\/000081416"},{"key":"e_1_2_7_38_1","doi-asserted-by":"publisher","DOI":"10.1186\/2047-783X-14-1-7"},{"key":"e_1_2_7_39_1","doi-asserted-by":"publisher","DOI":"10.1124\/jpet.102.038240"},{"key":"e_1_2_7_40_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ahj.2007.01.040"},{"key":"e_1_2_7_41_1","doi-asserted-by":"publisher","DOI":"10.1016\/0306-3623(79)90089-2"},{"key":"e_1_2_7_42_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0272-0590(83)80101-8"},{"key":"e_1_2_7_43_1","doi-asserted-by":"publisher","DOI":"10.1089\/jwh.1998.7.547"},{"key":"e_1_2_7_44_1","doi-asserted-by":"publisher","DOI":"10.1002\/pds.1155"},{"key":"e_1_2_7_45_1","doi-asserted-by":"publisher","DOI":"10.1097\/00004714-200304000-00013"},{"key":"e_1_2_7_46_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199909163411201"},{"key":"e_1_2_7_47_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.amjcard.2007.04.020"},{"key":"e_1_2_7_48_1","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2796.1999.00476.x"},{"key":"e_1_2_7_49_1","doi-asserted-by":"publisher","DOI":"10.1016\/0022-0736(89)90026-5"},{"key":"e_1_2_7_50_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1540-8167.2000.tb00033.x"},{"key":"e_1_2_7_51_1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.1993.03510210076031"},{"key":"e_1_2_7_52_1","first-page":"Cd008939","article-title":"QTc interval screening for cardiac risk in methadone treatment of opioid dependence","volume":"6","author":"Pani PP","year":"2013","journal-title":"Cochrane Database Syst Rev"}],"container-title":["Cardiovascular Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2F1755-5922.12120","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/1755-5922.12120","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,3]],"date-time":"2023-10-03T14:03:14Z","timestamp":1696341794000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/1755-5922.12120"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,5,12]]},"references-count":51,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2015,6]]}},"alternative-id":["10.1111\/1755-5922.12120"],"URL":"https:\/\/doi.org\/10.1111\/1755-5922.12120","archive":["Portico"],"relation":{},"ISSN":["1755-5914","1755-5922"],"issn-type":[{"value":"1755-5914","type":"print"},{"value":"1755-5922","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,5,12]]}}}